Literature DB >> 23574787

High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.

Cherifa Ayari1, Hélène LaRue, Hélène Hovington, André Caron, Alain Bergeron, Bernard Têtu, Vincent Fradet, Yves Fradet.   

Abstract

A prognostic value for tumor-associated macrophages (TAMs) and tumor-infiltrating dendritic cells (TIDCs) has been reported in many human cancers. The objective of this study is to determine the prognostic value of CD83(+) mature TIDCs and CD68(+) TAMs in non-muscle-invasive bladder cancer at first diagnosis. Immunohistochemistry staining was performed with anti-CD68 and anti-CD83 monoclonal antibodies on tissue sections from 93 formalin-fixed, paraffin-embedded tissue blocks from pTa and pT1 bladder tumors. A scoring index based on the average density of observed positive cells in the papillary axis, the stroma, lymphoid aggregates, and into tumor foci was calculated for each patient. Comparison of baseline characteristics with marker levels was done using Pearson χ(2) or Fisher exact test. Kaplan-Meier analyses and Cox regression models were fitted to evaluate the prognostic value of TIDCs and TAMs. The absence of both CD68(+) TAMs and CD83(+) TIDCs was associated with tumor recurrence. The presence of TIDCs was associated with a significant risk of progression to muscle-invasive cancer (hazard ratio, 8.253; P = .0179). Patients were risk stratified using age and TIDC score. Patients 70 years or older with a high score of TIDCs had a 56% progression-free survival after 6 years compared with 94% for patients younger than 70 years with a low score of TIDCs. None of 20 patients with a low score of TAMs progressed. These data indicate that the presence of mature TIDCs and possibly TAMs may help risk-stratify patients at the time of first diagnosis of non-muscle-invasive bladder cancer and may be useful in tailoring follow-up and treatment strategies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCG; Bacillus Calmette-Guérin; CI; CIS; DC; Dendritic cells; EORTC; European Organization for Research and Treatment of Cancer; HR; Macrophages; Non–muscle-invasive bladder cancer; Prognostic; TAM; TIDC; TUR; Tumor infiltration; carcinoma in situ; confidence interval; dendritic cells; hazard ratio; transurethral resection; tumor-associated macrophage; tumor-infiltrating dendritic cells

Mesh:

Year:  2013        PMID: 23574787     DOI: 10.1016/j.humpath.2013.01.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

Review 1.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

2.  Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.

Authors:  Zheng Liu; Yu Zhu; Le Xu; Junyu Zhang; Huyang Xie; Hangcheng Fu; Quan Zhou; Yuan Chang; Bo Dai; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

Review 3.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 4.  Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.

Authors:  Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk
Journal:  Nat Rev Urol       Date:  2022-03-31       Impact factor: 16.430

5.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

6.  Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin.

Authors:  Stephen B Williams; Ashish M Kamat; Chinedu Mmeje; Yuanquing Ye; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Oncotarget       Date:  2017-09-23

7.  Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count.

Authors:  Grzegorz Dyduch; Katarzyna Ewa Tyrak; Anna Glajcar; Joanna Szpor; Magdalena Ulatowska-Białas; Krzysztof Okoń
Journal:  Biomed Res Int       Date:  2017-02-26       Impact factor: 3.411

Review 8.  Inflammatory microenvironment in the initiation and progression of bladder cancer.

Authors:  Xinbing Sui; Liming Lei; Liuxi Chen; Tian Xie; Xue Li
Journal:  Oncotarget       Date:  2017-10-06

9.  Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.

Authors:  Shui-Qing Wu; Ran Xu; Xue-Feng Li; Xiao-Kun Zhao; Bin-Zhi Qian
Journal:  Oncotarget       Date:  2018-05-18

10.  Profiles of Immune Infiltration in Bladder Cancer and its Clinical Significance: an Integrative Genomic Analysis.

Authors:  Zonglong Wu; Kejia Zhu; Qinggang Liu; Yaxiao Liu; Lipeng Chen; Jianfeng Cui; Hongda Guo; Nan Zhou; Yaofeng Zhu; Yan Li; Benkang Shi
Journal:  Int J Med Sci       Date:  2020-03-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.